Alberto Gabizon

Alberto Gabizon co-developed Doxil (PEGylated liposomal doxorubicin), the first FDA-approved nano-drug for cancer, demonstrating that PEGylation extends liposome circulation time and reduces doxorubicin cardiotoxicity. His research established the clinical pharmacokinetic and pharmacodynamic principles of stealth liposomal drug delivery. He has contributed to clinical evaluation of liposomal formulations in breast, ovarian, and hematologic cancers.